Litifilimab
Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonal antibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of disorders such as systemic lupus erythematosus[1][2].